Summary
Ketanserin, a serotonin antagonist, has recently been developed. This agent produces antihemag-glutination and dilation of blood vessels. Blood pressure is also lowered by ketanserin. We investigated the effect of ketanserin on microhemodynamics and hemorheology in essential hypertension. Twenty patients with essential hypertension (8 males; 12 females; average age ±SE-56.2±2.5 years). A single dose of 10 mg ketanserin was given orally to each patient, without breakfast, on the experiment day. Ketanserin treatment resulted in: redution in systolic and diastolic blood pressure; significant decrease in heart rate; increase in arteriole and venule internal diameters; increase in blood flow velocities and blood flow volumes; significant decreases in whole blood viscosities at high shear rate (94.5 sec-1) and at low shear rate (0.376 sec-1), with no change in plasma viscosities; significant shortening of plasma passage times; and marked decreases in blood concentrations of total protein, albumin, and globulin. These data suggest that ketanserin benefically affects microhemodynamics and hemorheology.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Konishi M, Tsushima N, Sakakura M. Effect of bunazosin on microcirculation. Microcirculation Annual 1987:13–14.
Konishi M, Sakakura M, Tsushima N. Effects of ketanserin (KJK-945) on microcirculation in patients with essential hypertension. Microcirculation Annual 1988:27–28.
Tsushima N, Satoh T, Koyama T. Human microcirculation (MC) by intravital video-microscopic system (IVVMS). Bibl Anat 1981;20:716–719.
Tsushima N, Nakayama R. Microcirculation of bulbar conjunctiva. Excerpta Medica ICS. 1983;625:15–28.
Kikuchi Y, Arai T, Koyama T. Improved filtration method for red cell deformability measurement. Med Biol Eng Comput 1983;21:270–276.
Robertson JIS, Stott DJ, Ball SG. The serotonin antagonist ketanserin in the treatment of clinical hypertension: A short review. J Hypertens 1986;4(Suppl 5):119–121.
Vanhoutte PM, Ball SG, Berdeaux A, et al.. Mechanism of action of ketanserin. Trends Pharmacol Sci 1986;7:58–59.
Kalkuman HO, Timmermans PBWM, Van Zaieten PA. Characterization of the antihypertensive properties of ketanserin (R41 468) in rats. J Pharmacol Exp Ther 1982;222:227–231.
Wenting GJ, Man in't Veld AJ, Woittiez AJ. Haemodynamic effects of ketanserin, a selective 5-hydroxytryptamine (serotonin) receptor antagonist, in essential hypertension. Clin Sci 1982;63:4355–4388.
Vanhoutte PM, ed. Serotonin and the Cardiovascular System. New York; Raven Press, 1985.
Fagard R, Fiocchi R, Lijnen P. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J 1984;51:149–156.
Seibold JR, Terregino CA, Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold-induced vasoconstriction in primary Raynaud's phenomenon. J Rheumatol 1986;13:337–340.
Longstaff J, Gush EH, Williams SE. Effects of ketanserin, a novel serotonin antagonist on haemorheology and blood flow in patients with Raynaud's phenomenon. Abstracts of the Satellite Symposium to the 10th Scientific Meeting of the International Society of Hypertension. Serotonergic Mechanisms in the Cardiovascular System. Zurich: 1984:49.
Ernst E, Matrai A, Dormandy JA. Is there a correlation between red cell filterability and blood viscosity measurements? Clin Haemorheol 1981;1:335–340.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Konishi, M., Sakakura, M. & Tsushima, N. Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension. Cardiovasc Drug Ther 4, 101–104 (1990). https://doi.org/10.1007/BF00053438
Issue Date:
DOI: https://doi.org/10.1007/BF00053438